AskNadia: Does Taking One Baby Aspirin for Cardiovascular Benefit Men Only?

Hello Nadia, I read somewhere that the cardiovascular benefits of one baby aspirin a night only applies to men….is this true? My GP has me taking one baby aspirin at bed time due to my family history of cardiovascular disease (father, deceased of CHF at 65; first heart attack at age 50) although I show no signs/symptoms thus far (normal to low BP, clear cardiac

Read more

FDA Backtracks Over GLP-1s’ Effects on Pancreas

The U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a link between GLP-1 drugs used to treat type 2 diabetes and pancreatic maladies, including acute pancreatitis and pancreatic cancer. GLP-1 drugs, which work by stimulating the body to produce insulin, include Bristol-Myers Squibb’s Byetta and Bydureon, Merck’s Januvia and Janumet, and Novo Nordisk’s Victoza. However,

Read more

New Type 2 Drugs Change Treatment Decisions

Metformin, the cornerstone in treating type 2 diabetes, saw an increase in usage among type 2s from 23 percent of that population in 1997 to 53 percent in 2012. But that increase has since plateaued due to the introduction of additional drugs that target insulin secretion and glucose regulation. DPP-4 inhibitors, such as Januvia and Onglyza, now account for 21 percent of treatments. Long-acting insulins,

Read more

First-World Type 2 Drug Market to Reach $47 Billion by 2022

A Massachusetts-based research firm concludes that the first-world market for type 2 drugs and treatments will increase from $27 billion in sales in 2012 to $47 billion in 2022. The firm, Decision Resources, says increased sales in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom, will come from both an increase in the type 2 patient population and the introduction of

Read more

12th Q&A With Dr. Bernstein

Can Januvia Trigger Cancer Symptoms? I have been a type 2 diabetic for more than 10 years, and have been on Januvia for about half that time (previously Avandia). I recently read a Dr. Mercola piece where he said that Januvia may trigger some type of cancer symptoms because of how it impairs the bodies natural tumor fighting properties. I am 68 years old and

Read more

Am I Doing the Right Thing?

Readers occasionally ask us for advice about drugs they are taking. When they do, we refer their questions to a medical professional. In the question below, a Florida reader expresses concerns about the interaction of her diabetes drug with the medicines she takes for asthma. Dear Diabetes Health: I am asthmatic and was diagnosed with diabetes two or three years ago. I am 61 and

Read more

FDA OKs Sale of Combo Drug JANUMET

The FDA has approved US sales of JANUMET® XR, a daily oral treatment for type 2 diabetes that combines sitagliptin and extended-release metformin. The drug is the fourth oral type 2 diabetes treatment introduced by Merck, which also sells JANUVIA, JANUMET, and JUVISYNC. Sitagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor that reduces the production of glucagon, a pancreatic hormone that increases blood glucose levels. Metformin,

Read more

New Type 2 Drug Targets Blood Sugar and Cholesterol

Drug company Merck aims to give people with type 2 diabetes two treatments for the price of one. The new therapy, called Juvisync, was just approved by the US Food and Drug Administration. It’s not a radical new treatment, but instead a helpful combination of two familiar standbys: Juvisync unites the active ingredients in blood sugar-lowering Januvia and cholesterol-lowering Zocor in a single tablet. Why

Read more

Her Last-Minute Competition Entry Nets This Playwright Professor a $100,000 Grant

It’s late October, 2007, and Prof. Wendy Coleman has just learned about a competition called the Bayer Dream Fund. Coleman, a type 2 who was diagnosed in 2005, has been told that the fund grants a large cash award to the competition winner – money the winner can use to fund a personal project designed to spread the word about managing and living successfully with

Read more